A Novel Tumor Antigen and Foxp3 Dual Targeting Tumor Cell Vaccine Enhances the Immunotherapy in a Murine Model of Renal Cell Carcinoma
Technical Report,15 Sep 2013,14 Sep 2015
Health Research, Inc Buffalo United States
Pagination or Media Count:
A major barrier in vaccine therapy is represented by the presence of immunosuppressive factors predominant in cancer patients, such as regulatory T cells Tregs and suppressive myeloid cells, including myeloid derived suppressor cellsMDSCs and tumor associated macrophages TAMs. Here we report a tumor cell vaccine designed to target both tumor cells and Tregs by using Foxp3, a Treg-functional protein as an antigen in tumor cell vaccine. During first year of the project, we have demonstrated that the dual target vaccine had anti-tumor activity against established tumor. During last year, we tested a combination strategy to target suppressive myeloid cells MDSCs and TAMs with a pharmacological approach, tasquinimod, combined with dual targeting vaccine. The combination strategy prolonged survival, compared to vaccine single treatment. Overall, our results suggest that targeting immunosuppressive cells with vaccine or pharmacological strategies, results in greater anti-tumor activity and therapeutic efficacy, and provides foundation to test the strategy in clinical setting for patients with advanced, metastatic kidney cancer.